Clare Y Slaney

List of Publications by Year
in descending order

45	2,578	304368	301761
papers	citations	22 h-index	39 g-index

47	47	47	4874
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine, 2012, 18, 1224-1231.	15.2	406
2	Trafficking of T Cells into Tumors. Cancer Research, 2014, 74, 7168-7174.	0.4	313
3	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation, 2017, 127, 929-941.	3.9	251
4	Cathepsin B Inhibition Limits Bone Metastasis in Breast Cancer. Cancer Research, 2012, 72, 1199-1209.	0.4	173
5	CARs versus BiTEs: A Comparison between T Cellâ€“Redirection Strategies for Cancer Treatment. Cancer Discovery, 2018, 8, 924-934.	7.7	173
6	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. Frontiers in Immunology, 2018, 9, 70.	2.2	120
7	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Molecular Immunology, 2015, 67, 46-57.	1.0	100
8	BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity. Cancer Research, 2014, 74, 5091-5102.	0.4	99
9	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research, 2017, 23, 2478-2490.	3.2	95
10	Clinical application of genetically modified T cells in cancer therapy. Clinical and Translational Immunology, 2014, 3, e16.	1.7	94
11	Cellular networks controlling T cell persistence in adoptive cell therapy. Nature Reviews Immunology, 2021, 21, 769-784.	10.6	83
12	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3â^' Cellâ€“Mediated Modulation of CD103+ Dendritic Cells. Cancer Immunology Research, 2018, 6, 1069-1081.	1.6	67
13	Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer. Cancer Immunology Research, 2015, 3, 1207-1217.	1.6	63
14	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Cancer Research, 2017, 77, 1296-1309.	0.4	61
15	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology, 2016, 28, 64-72.	2.7	52
16	The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer. Cancer Research, 2013, 73, 5852-5857.	0.4	47
17	Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. , 2021, 9, e002555.		41
18	NaÃ¯ve blood monocytes suppress Tâ€cell function. A possible mechanism for protection from autoimmunity. Immunology and Cell Biology, 2011, 89, 7-13.	1.0	39

#	Article	IF	Citations
19	Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. Frontiers in Oncology, 2019, 9, 56.	1.3	36
20	CD73: A potential biomarker for anti-PD-1 therapy. OncoImmunology, 2015, 4, e1046675.	2.1	33
21	Glatiramer Acetate Treatment Directly Targets CD11b⁺Ly6G^{â^'} Monocytes and Enhances the Suppression of Autoreactive T cells in Experimental Autoimmune Encephalomyelitis. Scandinavian Journal of Immunology, 2011, 74, 235-243.	1.3	29
22	Novel combination immunotherapy for pancreatic cancer: potent antiâ€tumor effects with CD40 agonist and interleukinâ€15 treatment. Clinical and Translational Immunology, 2020, 9, e1165.	1.7	26
23	Enhancing chimeric antigen receptor Tâ€cell immunotherapy against cancer using a nanoemulsionâ€based vaccine targeting crossâ€presenting dendritic cells. Clinical and Translational Immunology, 2020, 9, e1157.	1.7	23
24	Tissueâ€specific tumor microenvironments influence responses to immunotherapies. Clinical and Translational Immunology, 2019, 8, e1094.	1.7	20
25	The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone. OncoImmunology, 2013, 2, e22339.	2.1	18
26	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy, 2015, 7, 499-512.	1.0	18
27	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 6222-6234.	3.2	17
28	Enterotoxins can support CAR T cells against solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25229-25235.	3.3	16
29	Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene. PLoS ONE, 2015, 10, e0136817.	1.1	14
30	Crossâ€talk between tumors at anatomically distinct sites. FEBS Journal, 2021, 288, 81-90.	2.2	9
31	Challenges and Opportunities for Effective Cancer Immunotherapies. Cancers, 2020, 12, 3164.	1.7	7
32	Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers. Immunotherapy Advances, 2021, 1, .	1.2	7
33	An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy. Oncotarget, 2017, 8, 115215-115229.	0.8	6
34	A modified superantigen rescues Ly6Gâ^'CD11b+blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE. Autoimmunity, 2013, 46, 269-278.	1.2	5
35	Primary and metastatic breast tumors cross-talk to influence immunotherapy responses. OncoImmunology, 2020, 9, 1802979.	2.1	5
36	Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma. Cancers, 2021, 13, 6342.	1.7	4

#	Article	IF	Citations
37	Releasing the Brake on Oncolytic Viral Therapy. Clinical Cancer Research, 2015, 21, 5417-5419.	3.2	3
38	Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses. Journal of Thoracic Disease, 2020, 12, 4504-4509.	0.6	3
39	Chimeric antigen receptor T cell therapies for thoracic cancersâ€" challenges and opportunities. Journal of Thoracic Disease, 2020, 12, 4510-4515.	0.6	1
40	Current status, challenges and perspectives: immunotherapy and tumour microenvironment in thoracic cancer. Journal of Thoracic Disease, 2020, 12, 4496-4497.	0.6	0
41	Abstract A104: Eradication of large solid tumors in immunocompetent mice using dual specific CAR T cells and vaccination. , 2016, , .		0
42	Abstract 631: Dual-specific T cells are highly effective in eradicating solid tumors. , 2017, , .		0
43	Abstract PR06: Dual-specific T-cells and an indirect vaccine eradicate large solid tumors. , 2019, , .		0
44	Abstract A048: Targeting the tumor microenvironment to enhance immunotherapy against cancer. , 2019, , .		0
45	453â€...Novel combination immunotherapy for boosting and priming immune responses in pancreatic cancer: strong anti-tumour effects with interleukin-15 and CD40 agonist treatment. , 2020, , .		0